Abstract 245P
Background
Cervical cancer ranked second on women in Indonesia with 23.4/100,000 population incidence and 13.9/100,000 population mortality, emphasizing the importance of its screening and prevention. Indonesian government have applied cancer “see and treat” method with visual inspection using acetic acid (VIA) followed by cryotherapy procedure, but the number of women complying with the program were only 5% despite 80% target in 2013. This study aimed to explore factors influencing women with VIA positive result’s likelihood to receive cryotherapy.
Methods
Our cross-sectional study observed “see and treat” program at Temanggung District Health Office, Central Java, Indonesia, between March 29 and April 31, 2018. We used simple random sampling technique to select 356 VIA possitive women aged 30-50 years and collected data on whether they underwent cryotherapy, their demographic profile, education, knowledge and awareness about cryotherapy, and family support using structured questionnaire. Data were analyzed with chi square analysis on STATA software.
Results
In our study, 217 women (60.69%) received cryotherapy, while 139 women (39.04%) did not. Among all variables analysed, factors affecting subjects’ likelihood to underwent cryotherapy are knowledge about cryotherapy itself (PR = 0.776, 95%CI=0.660-0.913, p = 0.003), residence distance (PR = 0.795, 95%CI=0.650-0.971, p = 0.016), permission from family (PR = 0.675, 95%CI=0.556-0.820, p = 0.018), and accompaniment by their family (PR = 0.824, 95%CI=0.700-0.970, p = 0.026). Age, marital status, occupation, and education background did not show significant correlation with women’s decision to receive cryotherapy.
Conclusions
Our study showed that more individuals with VIA positive results were willing to receive cryotherapy as an effort to prevent cervical cancer. However, our study also showed knowledge about cryotherapy, residence distance, family permission and family accompaniment as factors lowering VIA possitive women’s likelihood to receive cryotherapy. Because this study is only limited on Temanggung population, further study is needed to explore larger population and other factors that might also influence this behavior.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Funding
Board for Development and Empowerment Human Resources of Health, Ministry of Health Republic of Indonesia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract